Table 2 The relationship between HPV integration type and CIN2 + risk in each HPV integration reads strata
HPV integration reads | Women No. (%) | P value | ||
|---|---|---|---|---|
Total (N = 181) | Non-HPV16/18 integration (n = 64) | HPV16/18 integration (n = 117) | ||
6–20 | 69 (38.1) | 43 (67.2) | 26 (22.2) | - |
Immediate CIN2+ | 25 (36.2) | 13 (30.2) | 12 (46.2) | 0.206 |
1-year cumulative CIN2+ | 27 (39.1) | 14 (32.6) | 13 (50.0) | 0.204 |
21–40 | 16 (8.8) | 3 (4.6) | 13 (11.1) | - |
Immediate CIN2+ | 10 (62.5) | 2 (66.7) | 8 (61.5) | > 0.99 |
1-year cumulative CIN2+ | 11 (68.8) | 2 (66.7) | 9 (69.2) | > 0.99 |
41–200 | 35 (19.3) | 5 (7.8) | 30 (25.6) | - |
Immediate CIN2+ | 30 (85.7) | 3 (60.0) | 27 (80.0) | 0.139 |
1-year cumulative CIN2+ | 31 (88.6) | 4 (80.0) | 27 (80.0) | 0.477 |
201–1000 | 29 (16.0) | 6 (9.4) | 23 (19.7) | - |
Immediate CIN2+ | 28 (96.6) | 6 (100.0) | 22 (95.7) | > 0.99 |
1-year cumulative CIN2+ | 28 (96.6) | 6 (100.0) | 22 (95.7) | > 0.99 |
> 1000 | 32 (17.7) | 7 (11.0) | 25 (21.4) | - |
Immediate CIN2+ | 30 (93.8) | 7 (100.0) | 23 (92.0) | > 0.99 |
1-year cumulative CIN2+ | 31 (96.9) | 7 (100.0) | 24 (96.0) | > 0.99 |